If you or a loved one has been prescribed Spravato, one of the first questions on your mind is probably whether your health insurance will help cover the cost. Spravato insurance coverage is available through many major commercial insurers, Medicare, and Medicaid, but approval typically requires meeting specific clinical criteria and jumping through a few administrative hoops. Most patients with treatment-resistant depression or active suicidal ideation who have tried and failed at least two antidepressants can qualify. However, prior authorization is almost always required, and the process takes preparation.
The Guide to Spravato Insurance Coverage
If you or a loved one has been prescribed Spravato, one of the first questions on your mind is probably whether your health insurance will help cover the cost. Spravato insurance coverage is available through many major commercial insurers, Medicare, and Medicaid, but approval typically requires meeting specific clinical criteria and jumping through a few administrative hoops. Most patients with treatment-resistant depression or active suicidal ideation who have tried and failed at least two antidepressants can qualify. However, prior authorization is almost always required, and the process takes preparation.
Spravato is a prescription nasal spray developed by Janssen Pharmaceuticals. Its active ingredient, esketamine, is a derivative of ketamine – a well-known anesthetic that researchers discovered also has rapid antidepressant properties. Unlike traditional antidepressants that can take weeks to show results, Spravato can produce noticeable effects within hours or days for certain patients.
Because of its potential for misuse and dissociative side effects, Spravato is not a take-home medication. It must be administered in a certified healthcare setting, where patients are monitored for at least two hours after each dose. This delivery model plays a significant role in how insurance covers it and what you’ll pay.
Understanding what Spravato is approved to treat is the foundation of the entire insurance conversation. Insurers will only cover it for uses that meet their medical necessity criteria, which are closely tied to FDA indications.
Spravato received FDA approval in 2019 for treatment-resistant major depressive disorder (TRD) in adults. To qualify under this indication, a patient must have failed to respond adequately to at least two different antidepressant treatments during the current depressive episode. This is one of the most common pathways patients use to seek coverage.
In 2020, the FDA granted a second approval for Spravato to address depressive symptoms in adults with major depressive disorder who have active or imminent acute suicidal ideation or behavior (MDSI). This second indication opened the door for use in more urgent, inpatient, or crisis-adjacent settings, and many insurers cover it under similar prior authorization criteria.
Not all insurance policies treat Spravato the same way. Whether you have an employer-sponsored plan, an individual marketplace plan, or government coverage, the specifics of your insurance plan will determine your out-of-pocket costs, the required documentation for approval, and which providers are considered in-network.
Here are the key factors your insurer will likely evaluate:
Diagnosis confirmation: A formal diagnosis of treatment-resistant MDD or MDSI from a licensed psychiatrist or physician
Treatment history: Documentation showing prior antidepressant trials and their outcomes
Step therapy requirements: Some plans require patients to try specific medications before approving Spravato
In-network certified treatment centers: Coverage may only apply at REMS-certified facilities within your network
Prior authorization: Nearly all commercial plans require this before treatment begins
It is worth calling your insurer before your first appointment to request a benefits check. Ask specifically about your mental health benefits, specialty drug tier, and any step-therapy protocols that may apply.
Once approved, most commercial insurance plans cover Spravato under either the pharmacy benefit or the medical benefit, and which one applies matters more than you might think.
When covered under the medical benefit (which is more common, given the in-office administration), cost-sharing is typically calculated based on your plan’s specialist visit or infusion therapy copay structure.
Under a pharmacy benefit, you may face a specialty drug tier copay, which can be substantially higher.
The induction phase of treatment typically involves twice-weekly sessions for four weeks, followed by a maintenance phase of weekly or biweekly sessions. Over time, the cumulative cost of sessions, even with insurance, can add up. Patients report wide variability in their out-of-pocket experience depending on their deductible status and benefit tier.
For patients enrolled in government-sponsored programs, coverage is available but comes with its own nuances.
Medicare covers Spravato when administered in a physician’s office or an outpatient hospital setting. It generally falls under Medicare Part B, meaning it is treated as a physician-administered drug rather than a retail prescription. Patients are typically responsible for 20% of the Medicare-approved amount after the Part B deductible is met.
Medicaid coverage varies significantly by state. Some states require prior authorization for Spravato, while others have not yet included it in their formularies. If you are on Medicaid, contacting your state program directly or asking your treatment provider to help navigate the process is the most reliable approach.
TRICARE and VA benefits also cover Spravato for eligible veterans and military families, typically with prior authorization and documentation of treatment-resistant depression.
A common point of confusion is the distinction between Spravato and off-label ketamine therapy. While both involve ketamine-related compounds, they are treated very differently by insurance companies.
Off-label ketamine infusions, typically administered intravenously (via injection) by anesthesiologists or psychiatrists in private clinics, are not FDA-approved for depression. They are therefore almost universally excluded from insurance coverage. Patients pay entirely out of pocket, often $400 to $800 per infusion.
Spravato, by contrast, carries FDA approval and a certified treatment pathway, which is exactly why it is reimbursable. If cost is a primary concern and your provider has suggested ketamine infusions, it is worth asking whether you might be a candidate for Spravato instead, specifically because the insurance landscape is far more favorable.
The fact that Spravato is a nasal spray administered in a clinical setting – rather than a pill taken at home – is not just a safety measure. It directly shapes how the treatment is billed and covered. Because the drug is given under medical supervision, it qualifies as a “physician-administered drug” in most billing frameworks. This means it is often billed using a medical claim (CPT or HCPCS codes) rather than a pharmacy claim, which can work in your favor if your medical deductible is lower than your pharmacy deductible.
Even with insurance, Spravato can be expensive. Janssen offers a patient assistance program called Spravato WithMe, which provides copay support for eligible commercially insured patients. In some cases, it reduces out-of-pocket costs to as little as $10 per session. Uninsured or underinsured patients may qualify for the free medication program.
To access additional affordability support:
Visit the official Spravato WithMe website or ask your provider’s office for an enrollment form
Check whether your treatment center has a financial counselor who can assist with applications
Ask about state pharmaceutical assistance programs if you are on a fixed income
Explore nonprofit mental health organizations that offer treatment grants
Getting approved for Spravato is often just the beginning. Maintaining coverage through the maintenance phase requires continued documentation of treatment response and ongoing communication between your provider and insurer. Your treatment center’s billing team can be a vital ally in this process – they handle prior authorization renewals, appeals of denied claims, and communication with your plan.
If your claim is denied, do not give up. Many denials are successfully overturned on appeal, especially when a psychiatrist submits a letter of medical necessity outlining your treatment history and clinical response. Ongoing support from your care team and the Spravato WithMe program can make a meaningful difference in keeping treatment accessible over the long term.
Finding the right clinical setting for Spravato treatment can feel overwhelming, especially when you are already navigating a difficult diagnosis. Our healthcare providers listed in the directory have extensive experience with treatment-resistant depression, so you can feel confident you are starting your search in the right place. Whether you are exploring Spravato for the first time or considering alternative treatments alongside it, connecting with a qualified specialist early makes a real difference in your outcome. Many patients work with the same provider for up to one year or longer as they move through the induction and maintenance phases – so finding someone you trust is worth taking the time to get right.
Navigating Spravato coverage is undeniably complex, but the path forward is clearer than it might first appear. Most insurance providers, including commercial plans, Medicare, and Medicaid programs, do cover Spravato when the clinical criteria are met, and understanding that process from the start puts you in a much stronger position.
If you have already tried an oral antidepressant at an adequate dose and it has not worked, you likely meet one of the foundational requirements for approval. The approval process will ask your provider to carefully document that history, alongside monitoring considerations, such as blood pressure, which is checked as part of the broader risk evaluation and mitigation strategy built into Spravato’s certified treatment program.
If you are currently uninsured, exploring the health insurance marketplace or checking eligibility for Medicaid programs can open the door to low-cost health coverage that makes treatment financially viable. And even if gaps remain, the Johnson & Johnson Patient Assistance Program exists specifically to help patients access the medication they need. With the right diagnosis, the right provider, and the right support in place, Spravato can be a genuinely accessible option to treat depression when other approaches have fallen short.
